Previous close | 1.1200 |
Open | 1.1800 |
Bid | 1.0000 |
Ask | 1.1000 |
Strike | 10.00 |
Expiry date | 2024-10-18 |
Day's range | 1.1800 - 1.2000 |
Contract range | N/A |
Volume | |
Open interest | 1.08k |
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the 2024 Jefferies Global Healthcare Conference.
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Whitefort Capital wants biopharmaceutical firm Arbutus to stop issuing stock. Shah Capital ended a proxy campaign against biotech Novavax.